Release
📈 Stocks
PAVmed Reports Q3 2026 Results as Lucid Diagnostics Secures Medicare Coverage
(just now)
PAVmed shares outlook as subsidiary Lucid Diagnostics achieves nationwide Medicare reimbursement for EsoGuard, driving record test volumes in October 2026.